Valneva SE (VALN) Accumulated Expenses (2020 - 2026)
Valneva SE (VALN) posted Accumulated Expenses of $14.7 million for Q4 2025, up 5.07% sequentially from $14.0 million in Q4 2024, and up 5.07% YoY from $14.0 million in Q4 2024.
Analysis
Valneva SE (VALN) Accumulated Expenses (2020 - 2026) Analysis & Trends
Valneva SE has reported Accumulated Expenses for 6 years, with the latest figure at $14.7 million in Q4 2025.
- Quarterly Accumulated Expenses rose 5.07% year-over-year to $14.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.7 million (up 5.07% YoY) and the FY2025 annual result came in at $14.7 million, up 3.73% from the prior year.
- Accumulated Expenses climbed to $14.7 million in Q4 2025 per VALN's latest filing, from $14.0 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $14.7 million in Q4 2025 and troughed at $10.9 million in Q2 2024.
- A 5-year average of $12.3 million and a median of $11.6 million in 2021 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2024: Accumulated Expenses decreased 4.84% in 2022, then rose 20.37% in 2024.
- Over 5 years, Accumulated Expenses stood at $11.6 million in 2021, then slipped by 4.84% to $11.0 million in 2022, then climbed by 5.82% to $11.6 million in 2023, then climbed by 20.37% to $14.0 million in 2024, then increased by 5.07% to $14.7 million in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $14.7 million, $14.0 million, and $10.9 million for Q4 2025, Q4 2024, and Q2 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Valneva SE | 580.64 Mn | 439.38 Mn | 1.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 24.98 Mn |
| Mar 31, 2026 | 26.10 Mn |
| Dec 31, 2025 | 22.76 Mn |
| Sep 30, 2025 | 21.86 Mn |
| Jun 30, 2025 | 20.99 Mn |
| Mar 31, 2025 | 21.50 Mn |
| Dec 31, 2024 | 20.79 Mn |
| Sep 30, 2024 | 20.12 Mn |
| Jun 30, 2024 | 18.67 Mn |
| Mar 31, 2024 | 18.76 Mn |
| Dec 31, 2023 | 17.44 Mn |
| Sep 30, 2023 | 15.78 Mn |
| Jun 30, 2023 | 17.98 Mn |
| Mar 31, 2023 | 17.04 Mn |
| Dec 31, 2022 | 16.06 Mn |
| Sep 30, 2022 | 16.17 Mn |
| Jun 30, 2022 | 16.22 Mn |
| Dec 31, 2021 | 19.73 Mn |
| Dec 31, 2020 | 15.70 Mn |